Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves vs. Parkinson's: could ultrasound ease early symptoms?

NCT ID NCT06584383

First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 27 times

Summary

This study tests a non-invasive procedure called focused ultrasound on people with early-stage Parkinson's disease. It uses sound waves to target a small area in the brain involved in movement. The goal is to see if this treatment improves motor symptoms better than standard medication alone. About 67 participants will be randomly assigned to receive either the ultrasound procedure or continue with their usual medical care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • HM CINAC- Hospital Universitario HM Puerta del Sur

    Móstoles, 28938, Spain

  • Pontificia Universidad Catolica de Chile

    Santiago, Chile

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)

    Kiel, 24105, Germany

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Exablate MR-guided focused ultrasound (MRgFUS) subthalamotomy

What this could lead to

If successful, this could offer a non-invasive treatment option to reduce motor symptoms in early-stage Parkinson's disease, potentially delaying the need for stronger medications.

What could go wrong

This is an early-stage study with only 67 participants, so results may not apply to everyone. The procedure targets one side of the brain and may not address all symptoms, and there are risks like brain swelling or movement issues.

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.